Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination. - Kister, Ilya; Curtin, Ryan; Piquet, Amanda L.; Borko, Tyler; Pei, Jinglan; Banbury, Barbara L; Bacon, Tamar E.; Kim, Angie; Tuen, Michael; Velmurugu, Yogambigai; Nyovanie, Samantha; Selva, Sean; et al. (Annals of Clinical & Translational Neurology, 2024)